Pharma's New Manufacturing Playbook for Turbulent Times
No se pudo agregar al carrito
Solo puedes tener X títulos en el carrito para realizar el pago.
Add to Cart failed.
Por favor prueba de nuevo más tarde
Error al Agregar a Lista de Deseos.
Por favor prueba de nuevo más tarde
Error al eliminar de la lista de deseos.
Por favor prueba de nuevo más tarde
Error al añadir a tu biblioteca
Por favor intenta de nuevo
Error al seguir el podcast
Intenta nuevamente
Error al dejar de seguir el podcast
Intenta nuevamente
Pharma's New Manufacturing Playbook for Turbulent Times
-
Narrado por:
-
De:
Acerca de esta escucha
CDMO Live 2025 Highlights: How Bayer, Boehringer Ingelheim, and Leo Pharma are rebuilding manufacturing strategies
- Complexity Challenge: With thousands of SKUs to manage (Bayer handles 5,000+, half outsourced), companies struggle with aging portfolios and aggressive commercial expansion.
- Geopolitical Reshuffling: A staggering 62% of pharma companies are restructuring their manufacturing footprints in response to global tensions.
- Different Resilience Approaches:
- Boehringer Ingelheim (family-owned) maintains dual sourcing despite higher costs
- Leo Pharma focuses on strategic partnerships for smaller-volume products
- Bayer's "Project Martini" shifts from Euro-centric to regional production
- AI Adoption: Still early days, but promising applications in contract management, document processing, and predictive maintenance are emerging.
- Sustainability Shift: While not top priority, sustainability is increasingly viewed as both an ethical necessity and long-term cost reducer.
Bottom Line: The industry is moving from pure cost optimization to balancing affordability with resilience. As Blue Jet Healthcare's MD put it: "resilience is becoming as important as costs."
Download the full report
adbl_web_global_use_to_activate_T1_webcro805_stickypopup
Todavía no hay opiniones